Acutus Medical, Inc. Securities Investigation

03.15.2022

Our securities attorneys are investigating reports that Acutus Medical, Inc. may have made false and misleading statements regarding its business prospects.

Did you purchase or acquire Acutus shares between May 13, 2021 and November 11, 2021? Speak to a lawyer.

Protect your rights by speaking with a Girard Sharp investment fraud attorney. Call us toll-free at (866) 981-4800 or submit your information below:

Speak to a Lawyer






More Details on the Acutus Investigation

Acutus is an arrhythmia management company focused on improving the diagnosis and treatment of cardiac arrhythmias. The Company’s primary product is its AcQMap imaging and mapping system. In late 2019, Acutus began to install its second generation AcQMap console and workstation products with potential purchasers under evaluation arrangements. Pursuant to these agreements, Acutus places the AcQMap console and workstation with potential customers free of charge for a specified period. The Company then attempts to sell the console and workstation to the potential customers in exchange for a cash payment, or a contractual commitment to purchase a minimum amount of its disposable products.

Acutus reportedly experienced lower than expected rates of adoption at locations in which the AcQMap consoles and workstations were placed, but failed to disclose the sales results to investors until November 11, 2021, when Acutus announced that it had slashed its 2021 revenue guidance during the third quarter of 2021 to relocate approximately 20% of AcQMap systems installations under then-existing evaluation arrangements in order to address meaningfully lower-than-expected product adoption. Following this news, Acutus common stock plummeted more than 45% in a single day.

Did you purchase Acutus Medical, Inc. common stock between May 13, 2021 and November 11, 2021?

You may have a legal claim. Speak to an investment fraud attorney about your rights by calling 1.866.981.4800 or filling out the form at the top of the page.

Our Commitment to Excellence

Girard Sharp LLP represents investors, consumers, and institutions in class actions and other complex litigation nationwide. We serve on the Plaintiffs’ executive committee in the recent spoofing litigation against JPMorgan Chase that settled for $60 million, a favorable resolution that the district court preliminarily approved in December 2021. (S.D.N.Y. Case No. 1:18-cv-10356.) Our class action attorneys have obtained multimillion-dollar recoveries for victims of unfair and deceptive practices in antitrust, financial fraud, and consumer protection matters against some of the country’s largest corporations, including Raymond James, John Hancock, and Sears. Girard Sharp has earned top-tier rankings from U.S. News and World Report for Securities and Class Action Litigation and has been repeatedly selected as an Elite Trial Lawyers finalist by the National Law Journal.

Main Menu